Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / CRVS - Corvus' partner Angel Pharma gets nod to start phase 1/1b trial of cancer therapy in China

CRVS - Corvus' partner Angel Pharma gets nod to start phase 1/1b trial of cancer therapy in China

Corvus Pharmaceuticals Inc.

  • Clinical-stage biopharma Corvus Pharmaceuticals ( NASDAQ: CRVS ) on Monday said an investigational new drug application to start a phase 1/1b trial of monoclonal antibody mupadolimab had been approved by China's drug regulator.
  • The study was approved by the Center for Drug Evaluation of the China National Medical Products Administration, and will be conducted by Angel Pharmaceuticals, CRVS' partner in the Asian country.
  • Mupadolimab is being evaluated for the treatment of patients with relapsed refractory non-small cell lung cancer and head and neck squamous cell cancers.
  • Angel Pharma, a privately-held biopharma, was co-founded by CRVS to develop its pipeline in greater China.
  • Angel Pharma licensed the rights from CRVS to develop, make and commercialize mupadolimab in greater China, Corvus ( CRVS ) said in a statement .
  • CRVS stock +5% to $0.76 after hours.

For further details see:

Corvus' partner Angel Pharma gets nod to start phase 1/1b trial of cancer therapy in China
Stock Information
Company Name: Corvus Pharmaceuticals Inc.
Stock Symbol: CRVS
Market: NASDAQ
Website: corvuspharma.com
Menu
CRVS CRVS Quote CRVS Short CRVS News CRVS Articles CRVS Message Board
Get CRVS Alerts

News, Short Squeeze, Breakout and More Instantly...